Stryker Corporation

SYK · NYSE · USD

Can Stryker keep growing faster than its orthopaedic and MedSurg markets and expanding margins while absorbing higher tariffs and operational failures in a newly acquired business?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Robotic implant pull-through

    The bull case rests on Mako: every robot placed pulls knee and hip implants behind it, so growth depends more on installations than on the size of the market.

  • Steady product launch cadence

    A crowded launch calendar across orthopaedics and MedSurg lets Stryker grow faster than its end markets without depending on any single device.

  • Margin discipline through cost inflation

    Management has kept margins rising through tariffs and a cyber attack by holding spending tight and improving its product mix.

  • Cash funds deals and buybacks

    Strong cash generation and a lower debt load give Stryker room to keep buying companies while also returning money to shareholders.

Bear case

  • Sales guidance top end cut

    Management trimmed the top of its full-year sales range, tying the second half to how fast it can build and ship equipment that customers have already ordered.

  • Operational disruption risk

    A cyber attack and a single plant outage in peripheral vascular showed how quickly an operational failure at Stryker becomes lost sales and backorders.

  • Rising tariff and input costs

    Tariffs and raw material costs take a growing share of profit, and part of the latest earnings beat came from a tariff refund rather than from operations.

  • Payer reimbursement pressure

    Hospitals and government payers keep pressing on prices, and orthopaedic implant pricing stays slightly negative even while procedure volumes hold up.

Bull and bear points

Growth & Execution

In short: Mako placements and launches drive growth, while a cyber attack and plant outage slowed delivery.

Bull · 2

  • Mako installed base pulls through knee and hip implants

    With more than 3,000 systems placed and over two-thirds of its U.S. knees done on Mako, each installation locks in years of implant revenue for Stryker.

    Q4 FY2025 call

  • Launch calendar adds handheld robotics and trauma

    Full launch of the handheld Mako RPS, shoulder applications on the newest Mako, European Pangea and the Incompass ankle all arrive in the second half, giving Stryker fresh growth even if markets slow.

    Q2 FY2026 call
Bear · 2

  • Full-year sales outlook trimmed at the top end

    Six months ago management guided 2026 organic growth of 8% to 9.5%; it now says 8.3% to 9.3%, citing what it can actually produce and ship.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Peripheral vascular plant outage creates backorders

    A single Inari plant problem cost Stryker vascular sales in the second quarter and left a backorder management expects to clear only by the end of the third quarter, delaying the deal's promised growth.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins expand and cash flow is strong, while tariffs and cyber costs absorb part of the gain.

Bull · 2

  • Operating margin expands despite a larger tariff bill

    Operating margin reached 25.2% in the second quarter, though that quarter carried a net tariff benefit, and management still targets 150 basis points of expansion over three years.

    Q2 FY2026 call

  • Buybacks resume alongside dealmaking

    Acquisitions were repeatedly called the first use of cash with no buybacks; management now plans to resume repurchases this quarter, funded by $4.7 billion of trailing free cash flow.

    Tone shiftQ3 FY2025 → Q2 FY2026
Bear · 2

  • Cyber attack left unabsorbed factory overhead

    Shutting plants after the intrusion left idle-capacity costs, and management says remediation spending runs through the rest of the year, so the full-year margin gain leans on the second half.

    Q2 FY2026 call

  • Tariff bill doubles for 2026

    A year ago management sized tariffs at about $200 million and absorbed them; it now guides to roughly $400 million for 2026, with the extra $200 million landing in the first half.

    Tone shiftQ3 FY2025 → Q4 FY2025

Market Position

In short: Stryker leads in robotic knees and hips, but European approval delays and payer pricing pressure persist.

Bull · 2

  • Orthopaedics gains share faster than the market

    Management's 2026 plan assumes Stryker outgrows the orthopaedic market by 200 to 300 basis points, the same gap it has held for several years behind Mako and trauma products.

    Q1 FY2026 call

  • Procedure shift to surgery centers favors breadth

    Hips and knees done in ambulatory surgery centers have climbed into the high teens of procedures, and Stryker says its wide product range wins a large share of new center builds.

    Q2 FY2026 call
Bear · 2

  • European approval delays hold back key implants

    Pangea, Insignia and LIFEPAK reached Europe well after their U.S. launches because of slow regulatory review, which is why international growth trails the U.S. and why proposed reforms matter.

    Q4 FY2025 call

  • Payer pressure keeps orthopaedic pricing negative

    MedSurg carries positive price while orthopaedic implants stay slightly negative, and government and private payers keep pushing prices down across the portfolio.

    10-K, filed 2026-02-11